

EVIDENCE MAPPER: A NEW PLATFORM FOR SYSTEMATIC REVIEWS AND MAPPING EVIDENCE



"Designed by the people who do systematic reviews, our platform makes screening and reconciliation much easier and more efficient, saving us time and reducing errors."

Alison Martin, Director

Key messages

The Evidence Mapper is now available for subscribers.

Our popular platform is now available to other consultancies, pharmaceutical and biotech companies, academic centres and healthcare organisations.

The Evidence Mapper makes it easier for clients to drill down to find the papers on a specific topic.

Our clients get rapid access to up-to-date evidence and can easily drill down to find papers on their topic of interest.

Subscribers can use the Evidence Mapper platform to screen abstracts as well as develop Maps.

The expanded platform, designed by our in-house researchers who conduct systematic reviews, provides an efficient way of screening abstracts and reconciling conflicts that is ergonomic and easy to use, saving us time and making the process more accurate.

Indexing abstracts within an Evidence Map is an efficient way of shortlisting papers and drilling down into the evidence.

The user-friendly interface and in-built AI-inspired classifiers make indexing the content quick and easy.

Our consultancy still offers bespoke Evidence Maps for clients who don't have the resources to develop their own.

We are still very happy to develop Maps for clients as part of a systematic, targeted, or rapid review project.

The Evidence Mapper is now available for subscribers


Until now, Crystallise has been the only organisation able to develop Evidence Maps for our clients using this platform. We have now expanded the platform to be available as a subscription-based product, so your organization can develop your own Maps.

"We know that some clients would like to be able to develop their own Maps, and other consultancies would like to be able to use the platform for their clients without involving us."

The Evidence Mapper makes it easier for clients to drill down and find papers on a specific topic

Clients have their own secure domain, where they control who can access their Maps. They can't change the content and how it is indexed, but they can view their own Maps and drill down to see the citations reporting each outcome. These citations can then be downloaded as a .csv file with the details of the publication and its tags for further analysis, or a .ris file of the relevant citations, to incorporate into citation manager software. Other files, such as the report and slide deck associated with the project, or PDF files of key full-text publications, can also be uploaded by the client to the Resources page of each Map.

- The Map will automatically show you the tags for two of the fields just change the field name(s) to see a different display.
- You can now sort tags alphabetically A to Z and Z to A.
- You can select to focus the Map either on content indexed with a specific tag in a third field, or to exclude papers with a specific tag.
- When you export the details of a Map as a .csv file, you can choose whether to see individual tags or just groups of tags within each field.




Subscribers can use the Evidence Mapper platform to screen abstracts as well as develop Maps

"Designed by the people who do systematic reviews, our platform makes screening and reconciliation much easier and more efficient, saving us time and reducing errors." We know our clients really value the Evidence Maps we develop for them. But we do a lot more for clients than just develop Maps. The enhanced Evidence Mapper platform can now be used to upload, deduplicate and double screen thousands of abstracts as part of a literature review, with the option to create an Evidence Map

from the publications that have been included in the review.

The new platform allows Project Managers and Screening Managers to:

- Upload content from .ris, .nbib, .json files, .csv spreadsheets and manually, or import from another project.
- Deduplicate using our in-built deduper, which has proven <u>excellent accuracy</u>, saving you time.
- Allocate abstracts to one or multiple screeners and track screening progress.
- Review screening decisions and reconcile differences.
- See a summary of the flow of literature and automatically upload included abstracts into an Evidence Map.




Indexing abstracts within an Evidence Map is an efficient way of shortlisting papers and drilling down into the evidence

The Evidence Mapper platform allows subscribers to index each publication to a number of general or bespoke fields.

"Once all the papers are indexed, it is easy to drill down into the evidence."

We usually share the Map with the client and

agree the systematic strategy for shortlisting publications for inclusion in the full literature review, knowing the number of papers on each topic. Clients can then use the Map to identify the key papers for their business development or market access work from just a few weeks into a literature review project, while you carry on with data extraction and report writing.



The new Evidence Mapper platform allows you to:

- Use our in-built indexers to suggest relevant tags based on our pre-defined tag sets or your own list, saving indexing time.
- Index content to as many fields as you need, using our text highlighter to help identify relevant tags.
- Upload documents, spreadsheets, slide decks and other resources to keep all the materials for the project in one easily-accessible location.

We still offer bespoke Evidence Maps for clients who don't have the resources to develop their own

Many of our clients in pharmaceutical and biotech companies don't have the time to develop their own Maps. We are happy to include an Evidence Map as an interim deliverable as part of a systematic or targeted literature review, or as a key deliverable in a Rapid Review.

"Our clients really appreciate the Evidence Maps we develop for them. One Pharma client has asked us to produce more than 30 Maps so far."

Maps can be quickly updated, either to a planned

timetable or as key new evidence is published, and the rapid development time, typically just 4 to 6 weeks from starting the project, means that clients can always be up-to-date with the latest research. We have developed Evidence Maps for clients from the top 10 largest pharmaceutical companies down to small start-ups, and most of our clients come back for more.

If you'd like to arrange a call so we can show you how to use the new site, please email evidencemap@crystallise.com

Alternatively, you can try the new site out for free here.

Crystallise's insights & expertise

At Crystallise, we focus on synthesising and presenting evidence in a way that provides strategic support and medical insight for our clients. Our <u>Evidence Mapper platform</u> is ideal for collating a wide body of evidence so clients can drill down to find the studies they need for each location and topic. If you would like to hear more about this or our many other areas of research, please feel free to reach out.

References

Schlander, M., Hernandez-Villafuerte, K., Cheng, CY. et al. How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. *PharmacoEconomics* **39**, 1243–1269 (2021). https://doi.org/10.1007/s40273-021-01065-y



Crystallise Ltd

Follow us:



Email: contact@crystallise.com

Website: www.crystallise.com